Editorial commentary: Mass azithromycin distribution and emerging resistance: Taking a minimum harms approach

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1527-1529

  Malhotra Kumar, Surbhi ^a   Goossens, Herman ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; ERYTHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; DRUG TREATMENT FAILURE; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NOTE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRACHOMA; WORLD HEALTH ORGANIZATION; FEMALE; HETEROZYGOTE; MALE; MICROBIOLOGY; PNEUMOCOCCAL INFECTION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CARRIER STATE; FEMALE; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; TRACHOMA;

EID: 84877249432     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit139     Document Type: Note

References (17)

1. World Health Organization. Weekly epide-miological record: Progress report on elimination of trachoma, 2010. Available at: http://www. trachomacoalition.org/resources/who-weekly-epidemiological-record-progress- report-elimination-trachoma-2010. Accessed 5 March 2013.
2. Evans JR, Solomon AW. Antibiotics for trachoma. Cochrane Database Syst Rev 2011; CD001860.
3. Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009; 302:962-8.
4. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithro-mycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007; 369:482-90.
5. Goossens H, Ferech M, Vander SR, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-87.
6. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288-97.
7. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azi-thromycin- resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 2013; 56:1519-26.
8. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8:260-71.
9. Van HL, Coenen S, Lammens C, Hens N, Goossens H, Malhotra-Kumar S. Antimicrobial drug use and macrolide-resistant Streptococcus pyogenes, Belgium. Emerg Infect Dis 2012; 18:1515-8.
10. Maher MC, Alemayehu W, Lakew T, et al. The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the field. PLoS One 2012; 7:e29407.
11. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneu-moniae isolates. JAMA 2001; 286:1857-62.
12. Malhotra-Kumar S, Van Heirstraeten L, Coenen S, et al. Impact of amoxicillin therapy on oropharyngeal streptococci of patients with community-acquired lower respiratory tract infections. In: 51st ICAAC, 17-20 September 2011, Chicago, IL. Slide session: Emerging Issues in Managing Pneumonia. Presentation number L-1579.
13. Landman KZ, Kinabo GD, Schimana W, et al. Capacity of health-care facilities to deliver HIV treatment and care services, northern Tanzania, 2004. Int J STD AIDS 2006; 17:459-62.
14. Feikin DR, Dowell SF, Nwanyanwu OC, et al. Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis 2000; 181: 1501-5.
15. Gaynor BD, Holbrook KA, Whitcher JP, et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br J Ophthalmol 2003; 87:147-8.
16. Gebre T, Ayele B, Zerihun M, et al. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet 2012; 379:143-51.
17. Malhotra-Kumar S, Coenen S, Klugman KP, Goossens H. 3-monthly azithromycin administration for trachoma. Lancet 2009; 374:449-50.